Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Artificial Intelligence | Review

Advances in biomarkers and techniques for pancreatic cancer diagnosis

Authors: Haotian Wu, Suwen Ou, Hongli Zhang, Rui Huang, Shan Yu, Ming Zhao, Sheng Tai

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

Pancreatic cancer is the most lethal type of malignancy and is characterized by high invasiveness without severe symptoms. It is difficult to detect PC at an early stage because of the low diagnostic accuracy of existing routine methods, such as abdominal ultrasound, CT, MRI, and endoscopic ultrasound (EUS). Therefore, it is of value to develop new diagnostic techniques for early detection with high accuracy. In this review, we aim to highlight research progress on novel biomarkers, artificial intelligence, and nanomaterial applications on the diagnostic accuracy of pancreatic cancer.
Literature
1.
2.
Egawa S, et al. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas. 2012;41(7):985–92.PubMedCrossRef
3.
Buscail E, et al. Liquid biopsy approach for pancreatic ductal adenocarcinoma. Cancers (Basel). 2019;11(6):852.CrossRef
4.
Gandolfi L, et al. The role of ultrasound in biliary and pancreatic diseases. Eur J Ultrasound. 2003;16(3):141–59.PubMedCrossRef
5.
Francis IR. Pancreatic adenocarcinoma: diagnosis and staging using multidetector-row computed tomography (MDCT) and magnetic resonance imaging (MRI). Cancer Imaging. 2007;7 Spec No A(Special issue A):S160–5.PubMedCrossRef
6.
Fattahi R, et al. Pancreatic diffusion-weighted imaging (DWI): comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J Magn Reson Imaging. 2009;29(2):350–6.PubMedCrossRef
7.
Treadwell JR, et al. Imaging tests for the diagnosis and staging of pancreatic adenocarcinoma: a meta-analysis. Pancreas. 2016;45(6):789–95.PubMedCrossRef
8.
Kurihara K, Hanada K, Shimizu A. Endoscopic ultrasonography diagnosis of early pancreatic cancer. Diagnostics (Basel). 2020;10(12):1086.CrossRef
9.
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–70.PubMedCrossRef
10.
Scara S, Bottoni P, Scatena R. CA 19-9: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:247–60.PubMedCrossRef
11.
Ferrone CR, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24(18):2897–902.PubMedCrossRef
12.
Wu Z, Kuntz AI, Wadleigh RG. CA 19-9 tumor marker: is it reliable? A case report in a patient with pancreatic cancer. Clin Adv Hematol Oncol. 2013;11(1):50–2.PubMed
13.
Gu YL, et al. Applicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy. Asian Pac J Cancer Prev. 2015;16(15):6569–73.PubMedCrossRef
14.
15.
Henriksen SD, et al. Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma. Oncotarget. 2017;8(55):93942–56.PubMedPubMedCentralCrossRef
16.
BACALBASA N, et al. Does sentinel node biopsy play a role in pancreatic adenocarcinoma? J Arch Balkan Med Union. 2019;54(2):334–8.CrossRef
17.
18.
Eissa MAL, et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin Epigenet. 2019;11(1):59.CrossRef
19.
Nishizawa N, et al. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer. Cancer Sci. 2019;110(9):2846–55.PubMedPubMedCentralCrossRef
20.
Kisiel JB, et al. New DNA methylation markers for pancreatic cancer: discovery, tissue validation, and pilot testing in pancreatic juice. Clin Cancer Res. 2015;21(19):4473–81.PubMedPubMedCentralCrossRef
21.
Schultz NA, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014;311(4):392–404.PubMedCrossRef
22.
23.
Yu Y, et al. Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer. Medicine (Baltimore). 2020;99(52): e23863.CrossRef
24.
25.
26.
Debernardi S, et al. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. Am J Cancer Res. 2015;5(11):3455–66.PubMedPubMedCentral
27.
Yang JY, et al. MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. Am J Cancer Res. 2014;4(6):663–73.PubMedPubMedCentral
28.
Machida T, et al. miR-1246 and miR-4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. Oncol Rep. 2016;36(4):2375–81.PubMedCrossRef
29.
Ma Z, et al. Long non-coding RNA SNHG15 inhibits P15 and KLF2 expression to promote pancreatic cancer proliferation through EZH2-mediated H3K27me3. Oncotarget. 2017;8(48):84153–67.PubMedPubMedCentralCrossRef
30.
Guo XB, Yin HS, Wang JY. Evaluating the diagnostic and prognostic value of long non-coding RNA SNHG15 in pancreatic ductal adenocarcinoma. Eur Rev Med Pharmacol Sci. 2018;22(18):5892–8.PubMed
31.
32.
33.
34.
Li J, et al. Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J Exp Clin Cancer Res. 2018;37(1):177.PubMedPubMedCentralCrossRef
35.
Li Z, et al. Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer. Cancer Lett. 2018;432:237–50.PubMedCrossRef
36.
Shen X, et al. Identification of Circ_001569 as a potential biomarker in the diagnosis and prognosis of pancreatic cancer. Technol Cancer Res Treat. 2021;20:1533033820983302.PubMedPubMedCentralCrossRef
37.
38.
39.
Sun L, et al. CPA4 is a promising diagnostic serum biomarker for pancreatic cancer. Am J Cancer Res. 2016;6(1):91–6.PubMed
40.
Sogawa K, et al. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. Br J Cancer. 2016;115(8):949–56.PubMedPubMedCentralCrossRef
41.
Fukutake N, et al. A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLoS ONE. 2015;10(7):e0132223.PubMedPubMedCentralCrossRef
42.
Kaur S, et al. A combination of MUC5AC and CA19-9 improves the diagnosis of pancreatic cancer: a multicenter study. Am J Gastroenterol. 2017;112(1):172–83.PubMedCrossRef
43.
Poruk KE, et al. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas. 2013;42(2):193–7.PubMedPubMedCentralCrossRef
44.
Radon TP, et al. Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma. Clin Cancer Res. 2015;21(15):3512–21.PubMedPubMedCentralCrossRef
45.
Hogendorf P, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: preliminary report. Cancer Biomark. 2016;16(4):537–43.PubMedCrossRef
46.
47.
Zhang WH, et al. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: a systems biology perspective. Comput Struct Biotechnol J. 2020;18:3606–14.PubMedPubMedCentralCrossRef
48.
Terai K, et al. Levels of soluble LR11/SorLA are highly increased in the bile of patients with biliary tract and pancreatic cancers. Clin Chim Acta. 2016;457:130–6.PubMedCrossRef
49.
Du T, et al. The diagnosis and staging of pancreatic cancer: a comparison of endoscopic ultrasound and computed tomography with pancreas protocol. Am J Surg. 2018;215(3):472–5.PubMedCrossRef
50.
Walczak S, Velanovich V. An evaluation of artificial neural networks in predicting pancreatic cancer survival. J Gastrointest Surg. 2017;21(10):1606–12.PubMedCrossRef
51.
Le Berre C, et al. Application of artificial intelligence to gastroenterology and hepatology. Gastroenterology. 2020;158(1):76-94.e2.PubMedCrossRef
52.
Liang M, et al. Low-dose CT screening for lung cancer: computer-aided detection of missed lung cancers. Radiology. 2016;281(1):279–88.PubMedCrossRef
53.
Le MH, et al. Automated diagnosis of prostate cancer in multi-parametric MRI based on multimodal convolutional neural networks. Phys Med Biol. 2017;62(16):6497–514.PubMedCrossRef
54.
Lu Y, et al. Identification of metastatic lymph nodes in MR imaging with faster region-based convolutional neural networks. Cancer Res. 2018;78(17):5135–43.PubMedCrossRef
55.
Li X, et al. Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study. Lancet Oncol. 2019;20(2):193–201.PubMedCrossRef
56.
Goyal H, et al. Application of artificial intelligence in pancreaticobiliary diseases. Ther Adv Gastrointest Endosc. 2021;14:2631774521993059.PubMedPubMedCentral
57.
Prasoppokakorn T, et al. Application of artificial intelligence for diagnosis of pancreatic ductal adenocarcinoma by EUS: a systematic review and meta-analysis. Endosc Ultrasound. 2022;11(1):17–26.PubMed
58.
Chassagnon G, et al. Artificial intelligence applications for thoracic imaging. Eur J Radiol. 2020;123:108774.PubMedCrossRef
59.
Sheth D, Giger ML. Artificial intelligence in the interpretation of breast cancer on MRI. J Magn Reson Imaging. 2020;51(5):1310–24.PubMedCrossRef
60.
Liu KL, et al. Deep learning to distinguish pancreatic cancer tissue from non-cancerous pancreatic tissue: a retrospective study with cross-racial external validation. Lancet Digit Health. 2020;2(6):e303–13.PubMedCrossRef
61.
Liu SL, et al. Establishment and application of an artificial intelligence diagnosis system for pancreatic cancer with a faster region-based convolutional neural network. Chin Med J (Engl). 2019;132(23):2795–803.CrossRef
62.
Gao X, Wang X. Performance of deep learning for differentiating pancreatic diseases on contrast-enhanced magnetic resonance imaging: a preliminary study. Diagn Interv Imaging. 2020;101(2):91–100.PubMedCrossRef
63.
Li S, et al. An effective computer aided diagnosis model for pancreas cancer on PET/CT images. Comput Methods Progr Biomed. 2018;165:205–14.CrossRef
64.
Das A, et al. Digital image analysis of EUS images accurately differentiates pancreatic cancer from chronic pancreatitis and normal tissue. Gastrointest Endosc. 2008;67(6):861–7.PubMedCrossRef
65.
Zhu M, et al. Differentiation of pancreatic cancer and chronic pancreatitis using computer-aided diagnosis of endoscopic ultrasound (EUS) images: a diagnostic test. PLoS ONE. 2013;8(5):e63820.PubMedPubMedCentralCrossRef
66.
Săftoiu A, et al. Quantitative contrast-enhanced harmonic EUS in differential diagnosis of focal pancreatic masses (with videos). Gastrointest Endosc. 2015;82(1):59–69.PubMedCrossRef
67.
Momeni-Boroujeni A, Yousefi E, Somma J. Computer-assisted cytologic diagnosis in pancreatic FNA: an application of neural networks to image analysis. Cancer Cytopathol. 2017;125(12):926–33.PubMedCrossRef
68.
Zhang K, et al. Clinically applicable AI system for accurate diagnosis, quantitative measurements, and prognosis of COVID-19 pneumonia using computed tomography. Cell. 2020;181(6):1423-1433.e11.PubMedPubMedCentralCrossRef
69.
Yang Y, et al. Diagnosis of pancreatic carcinoma based on combined measurement of multiple serum tumor markers using artificial neural network analysis. Chin Med J (Engl). 2014;127(10):1891–6.
70.
Lee J, et al. Identification of circulating serum miRNAs as novel biomarkers in pancreatic cancer using a penalized algorithm. Int J Mol Sci. 2021;22(3):1007.PubMedPubMedCentralCrossRef
71.
Burke BP, Cawthorne C, Archibald SJ. Multimodal nanoparticle imaging agents: design and applications. Philos Trans A Math Phys Eng Sci. 2017;375(2107):20170261.PubMed
72.
Asem H, et al. Biodistribution of biodegradable polymeric nano-carriers loaded with busulphan and designed for multimodal imaging. J Nanobiotechnol. 2016;14(1):82.CrossRef
73.
Barrefelt Å, et al. Fluorescence labeled microbubbles for multimodal imaging. Biochem Biophys Res Commun. 2015;464(3):737–42.PubMedCrossRef
74.
Ye F, et al. Advances in nanotechnology for cancer biomarkers. J Nano Today. 2018;18:103–23.CrossRef
75.
Hahn MA, et al. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal Bioanal Chem. 2011;399(1):3–27.PubMedCrossRef
76.
Rosenberger I, et al. Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. J Control Release. 2015;214:76–84.PubMedCrossRef
77.
Luo Y, et al. Hyaluronic acid-mediated multifunctional iron oxide-based MRI nanoprobes for dynamic monitoring of pancreatic cancer. RSC Adv. 2019;9:10486–93.PubMedPubMedCentralCrossRef
78.
Boyer C, et al. The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications. NPG Asia Mater. 2009;2:23–30.CrossRef
79.
80.
81.
Sun X, et al. Tracking stem cells and macrophages with gold and iron oxide nanoparticles-The choice of the best suited particles. Appl Mater Today. 2019;15:267–79.CrossRef
82.
Zhuo Y, et al. Functionalized SiO2 labeled CA19-9 antibodies: a new strategy for signal amplification of antigen-antibody sensing processes. Analyst. 2010;135(8):2036–42.PubMedCrossRef
83.
Jin W, et al. A simple MWCNTs@paper biosensor for CA19-9 detection and its long-term preservation by vacuum freeze drying. Int J Biol Macromol. 2020;144:995–1003.PubMedCrossRef
84.
Morgan NY, et al. Real time in vivo non-invasive optical imaging using near-infrared fluorescent quantum dots. Acad Radiol. 2005;12(3):313–23.PubMedCrossRef
85.
Raffa V, et al. Progress in nanotechnology for healthcare. Minim Invasive Ther Allied Technol. 2010;19(3):127–35.PubMedCrossRef
86.
Gu B, et al. ZnO quantum dot labeled immunosensor for carbohydrate antigen 19–9. Biosens Bioelectron. 2011;26(5):2720–3.PubMedCrossRef
87.
Kumar R, et al. Covalently dye-linked, surface-controlled, and bioconjugated organically modified silica nanoparticles as targeted probes for optical imaging. ACS Nano. 2008;2(3):449–56.PubMedCrossRef
Metadata
Title
Advances in biomarkers and techniques for pancreatic cancer diagnosis
Authors
Haotian Wu
Suwen Ou
Hongli Zhang
Rui Huang
Shan Yu
Ming Zhao
Sheng Tai
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02640-9

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Primary Research

CD98hc has a pivotal role in maintaining the immuno-barrier integrity of basal layer cells in esophageal epithelium

Research

Oleic acid from cancer-associated fibroblast promotes cancer cell stemness by stearoyl-CoA desaturase under glucose-deficient condition

Research

N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma

Research

Transcription factor c-Rel regulated by E5 affects the whole process after HPV16 infection through miR-133a-modulated feedback loop aim at mir-379-369 cluster

Review

Early versus delay oral feeding for patients after upper gastrointestinal surgery: a systematic review and meta-analysis of randomized controlled trials

Research

HOXC6 impacts epithelial-mesenchymal transition and the immune microenvironment through gene transcription in gliomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits